Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 967 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults June 15, 2023 Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... January 24, 2022 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 Load more HOT NEWS Rare Identical Twins Born With Different Body Sizes Get Mistaken For... “Nothing about us without us”: Why we’re working in partnership with... Breaking News: The Healthcare Marketplace Re-opens TODAY! Foodie Friday: It’s Berry Season!
